BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 20573862)

  • 1. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer.
    Ratnam S; Coutlee F; Fontaine D; Bentley J; Escott N; Ghatage P; Gadag V; Holloway G; Bartellas E; Kum N; Giede C; Lear A
    J Clin Microbiol; 2010 Aug; 48(8):2779-85. PubMed ID: 20573862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer.
    Ratnam S; Coutlee F; Fontaine D; Bentley J; Escott N; Ghatage P; Gadag V; Holloway G; Bartellas E; Kum N; Giede C; Lear A
    J Clin Microbiol; 2011 Feb; 49(2):557-64. PubMed ID: 21147950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens.
    Keegan H; Mc Inerney J; Pilkington L; Grønn P; Silva I; Karlsen F; Bolger N; Logan C; Furuberg L; O'Leary J; Martin C
    J Virol Methods; 2009 Jan; 155(1):61-6. PubMed ID: 18955086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of ProEx C and PreTect HPV-Proofer E6/E7 mRNA tests in comparison with the hybrid capture 2 HPV DNA test for triaging ASCUS and LSIL cytology.
    Alaghehbandan R; Fontaine D; Bentley J; Escott N; Ghatage P; Lear A; Coutlee F; Ratnam S
    Diagn Cytopathol; 2013 Sep; 41(9):767-75. PubMed ID: 23341349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test.
    Benevolo M; Vocaturo A; Caraceni D; French D; Rosini S; Zappacosta R; Terrenato I; Ciccocioppo L; Frega A; Giorgi Rossi P
    J Clin Microbiol; 2011 Jul; 49(7):2643-50. PubMed ID: 21525231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia.
    Tropé A; Sjøborg K; Eskild A; Cuschieri K; Eriksen T; Thoresen S; Steinbakk M; Laurak V; Jonassen CM; Westerhagen U; Jacobsen MB; Lie AK
    J Clin Microbiol; 2009 Aug; 47(8):2458-64. PubMed ID: 19535524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear.
    Molden T; Nygård JF; Kraus I; Karlsen F; Nygård M; Skare GB; Skomedal H; Thoresen SO; Hagmar B
    Int J Cancer; 2005 May; 114(6):973-6. PubMed ID: 15645423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantivirus® HPV E6/E7 RNA 3.0 assay (bDNA) is as sensitive, but less specific than Hybrid Capture 2 test.
    Shen Y; Gong J; He Y; Cheng G; Okunieff P; Li X
    J Virol Methods; 2013 Feb; 187(2):288-93. PubMed ID: 23201290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology.
    Rijkaart DC; Heideman DA; Coupe VM; Brink AA; Verheijen RH; Skomedal H; Karlsen F; Morland E; Snijders PJ; Meijer CJ
    J Clin Microbiol; 2012 Jul; 50(7):2390-6. PubMed ID: 22553244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion.
    Molden T; Kraus I; Karlsen F; Skomedal H; Nygård JF; Hagmar B
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):367-72. PubMed ID: 15734959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of Viral Oncogene E6-E7 mRNA Overexpression in a Population-Based Large Sample of Women Infected by High-Risk Human Papillomavirus Types.
    Giorgi Rossi P; Bisanzi S; Allia E; Mongia A; Carozzi F; Gillio-Tos A; De Marco L; Ronco G; Gustinucci D; Del Mistro A; Frayle H; Iossa A; Fantacci G; Pompeo G; Cesarini E; Bulletti S; Passamonti B; Rizzi M; Penon MG; Barca A; Benevolo M
    J Clin Microbiol; 2017 Apr; 55(4):1056-1065. PubMed ID: 28100595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas.
    Kraus I; Molden T; Holm R; Lie AK; Karlsen F; Kristensen GB; Skomedal H
    J Clin Microbiol; 2006 Apr; 44(4):1310-7. PubMed ID: 16597856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of oncogenic HPV type-specific viral DNA load and E6/E7 mRNA detection in cervical samples: results from a multicenter study.
    Broccolo F; Fusetti L; Rosini S; Caraceni D; Zappacosta R; Ciccocioppo L; Matteoli B; Halfon P; Malnati MS; Ceccherini-Nelli L
    J Med Virol; 2013 Mar; 85(3):472-82. PubMed ID: 23280876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers.
    Basu P; Banerjee D; Mittal S; Dutta S; Ghosh I; Chowdhury N; Abraham P; Chandna P; Ratnam S
    J Med Virol; 2016 Jul; 88(7):1271-8. PubMed ID: 26693677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction.
    Sotlar K; Stubner A; Diemer D; Menton S; Menton M; Dietz K; Wallwiener D; Kandolf R; Bültmann B
    J Med Virol; 2004 Sep; 74(1):107-16. PubMed ID: 15258976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PreTect HPV-Proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses.
    Molden T; Kraus I; Skomedal H; Nordstrøm T; Karlsen F
    J Virol Methods; 2007 Jun; 142(1-2):204-12. PubMed ID: 17379322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Value of Human Papillomavirus E6/E7 mRNA Detection in Screening for Cervical Cancer in Women Positive for Human Papillomavirus DNA or.
    Han L; Husaiyin S; Zhao F; Rezhake R; Niyazi M
    Clin Lab; 2018 Sep; 64(9):1363-1371. PubMed ID: 30274003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical performance of Anyplex II HPV28 by human papillomavirus type and viral load in a referral population.
    Baasland I; Romundstad PR; Eide ML; Jonassen CM
    PLoS One; 2019; 14(1):e0210997. PubMed ID: 30673759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MassARRAY spectrometry is more sensitive than PreTect HPV-Proofer and consensus PCR for type-specific detection of high-risk oncogenic human papillomavirus genotypes in cervical cancer.
    Basu P; Chandna P; Bamezai RN; Siddiqi M; Saranath D; Lear A; Ratnam S
    J Clin Microbiol; 2011 Oct; 49(10):3537-44. PubMed ID: 21813716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPV E6/E7 mRNA testing is more specific than cytology in post-colposcopy follow-up of women with negative cervical biopsy.
    Sørbye SW; Arbyn M; Fismen S; Gutteberg TJ; Mortensen ES
    PLoS One; 2011; 6(10):e26022. PubMed ID: 21998748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.